Logo do repositório
 
Publicação

Expert perspectives on the use of safinamide for Parkinson’s disease in Portugal : insights from a Portuguese Delphi Consensus

2025-07Contributo em revista Acesso aberto
Ver registo simples
datacite.subject.fosCiências Médicas::Ciências da Saúde
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorRodrigues, Ana Margarida
dc.contributor.authorCosta, Cristina
dc.contributor.authorGago, Miguel
dc.contributor.authorGrunho, Miguel
dc.contributor.authorGuedes, Leonor Correia
dc.contributor.authorMorgadinho, Ana
dc.contributor.authorRosas, Maria José
dc.contributor.authorSimões, Rita
dc.contributor.authorVelon, Ana Graça
dc.date.accessioned2026-05-07T13:52:53Z
dc.date.available2026-05-07T13:52:53Z
dc.date.issued2025-07
dc.description.abstractAim: Safinamide is an approved medication for managing motor fluctuations in Parkinson’s disease (PD). However, limited data exist regarding its application in clinical practice in Portugal and the perspectives of Portuguese neurologists on its use. To address this, a group of Portuguese specialists with recognized expertise in PD management convened to compile the insights on various aspects of safinamide use in PD patients among the field and to develop recommendations aimed at informing and guiding physicians in Portugal on its optimal clinical application. Materials & methods: A focus group composed of nine Portuguese PD experts developed a questionnaire building on the 2022 European Delphi study, and employed a Delphi methodology approach to gather the views of Portuguese neurologists with a minimum of 5 years of clinical experience with safinamide (n = 35). A final online questionnaire comprising 35 statements was administered in a single-round Delphi format, utilizing a 5-point Likert scale. Consensus was defined as achieving ≥66% agreement or disagreement among the panelists. Results: A strong consensus emerged among Portuguese neurologists regarding the therapeutic efficacy of safinamide in addressing motor symptoms, motor fluctuations and quality of life. Additionally, agreement was reached on its positive effects on nonmotor symptoms such as sleep, fatigue, mood, quality of life and pain management. However, no consensus was achieved regarding safinamide’s efficacy in managing orthostatic hypotension, cognitive issues, urinary and sexual dysfunction, as well as its safety profile in PD patients with hallucinations. Overall, the opinions of Portuguese neurologists aligned closely with those of their European counterparts. Conclusion: This Delphi study highlights the consensus among Portuguese neurologists on the efficacy of safinamide for managing motor symptoms in PD. The considerations presented herein offer essential guidance for effectively managing PD with safinamide, ultimately enhancing patient care in Portugal.eng
dc.identifier.citationAna Margarida Rodrigues, Cristina Costa, Miguel Gago, Miguel Grunho, Leonor Correia Guedes, Ana Morgadinho, Maria José Rosas, Rita Simões, and Ana Graça Velon Expert perspectives on the use of safinamide for Parkinson’s disease in Portugal: insights from a Portuguese Delphi Consensus. (2025) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2024-0228
dc.identifier.doi10.57264/cer-2024-0228
dc.identifier.issn2042-6313
dc.identifier.urihttp://hdl.handle.net/10400.26/63025
dc.language.isoeng
dc.peerreviewedyes
dc.publisherBecaris
dc.relation.hasversionhttps://doi.org/10.57264/cer-2024-0228
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectDelphi
dc.subjectdyskinesia
dc.subjectefficacy
dc.subjectfluctuations
dc.subjectmotor symptoms
dc.subjectnonmotor symptoms
dc.subjectParkinson's disease
dc.subjectPortugal
dc.subjectsafety
dc.subjectsafinamide
dc.titleExpert perspectives on the use of safinamide for Parkinson’s disease in Portugal : insights from a Portuguese Delphi Consensuseng
dc.typecontribution to journal
dspace.entity.typePublication
oaire.citation.issue7
oaire.citation.startPagee240228
oaire.citation.titleJournal of Comparative Effectiveness Research
oaire.citation.volume14
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Artigo_MGrunho_2025_01.pdf
Tamanho:
1.54 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.85 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

EM - Artigos Científicos